175 related articles for article (PubMed ID: 21393192)
1. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.
Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
J Antimicrob Chemother; 2011 Apr; 66(4):840-4. PubMed ID: 21393192
[TBL] [Abstract][Full Text] [Related]
2. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Blondeau JM; Borsos S; Hesje CK
J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
[TBL] [Abstract][Full Text] [Related]
4. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
5. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy.
Kowalski RP; Kowalski BR; Romanowski EG; Mah FS; Thompson PP; Gordon YJ
Am J Ophthalmol; 2006 Nov; 142(5):730-5. PubMed ID: 16978577
[TBL] [Abstract][Full Text] [Related]
6. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
7. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
[TBL] [Abstract][Full Text] [Related]
8. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Donnenfeld ED; Comstock TL; Proksch JW
J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Norcross EW; Sanders ME; Moore Q; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Jun; 26(3):237-43. PubMed ID: 20565309
[TBL] [Abstract][Full Text] [Related]
10. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
J Antimicrob Chemother; 2010 Jul; 65(7):1441-7. PubMed ID: 20435780
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability.
Donnenfeld E; Perry HD; Chruscicki DA; Bitterman A; Cohn S; Solomon R
Curr Med Res Opin; 2004 Nov; 20(11):1753-8. PubMed ID: 15537475
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of fourth-generation fluoroquinolones on corneal re-epithelialization in rabbit eyes.
Moshirfar M; Chew J; Werner L; Meyer JJ; Hunter B; Stevens S; Jensen M; Kleinmann G; Mamalis N
Graefes Arch Clin Exp Ophthalmol; 2008 Oct; 246(10):1455-61. PubMed ID: 18642018
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
16. The dilution of benzalkonium chloride (BAK) in the tear film.
Friedlaender MH; Breshears D; Amoozgar B; Sheardown H; Senchyna M
Adv Ther; 2006; 23(6):835-41. PubMed ID: 17276951
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride.
Blondeau J; DeCory H
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34072129
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Ozdek SC; Miller D; Flynn PM; Flynn HW
Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
[TBL] [Abstract][Full Text] [Related]
19. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
Kim DH; Stark WJ; O'Brien TP; Dick JD
Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
